Alvogen Wins Generic Zohydro Case Over Pernix Patents

Law360 (August 27, 2018, 8:05 PM EDT) -- Alvogen Malta Operations Ltd. on Friday scored a win in its effort to invalidate two Pernix patents for the hydrocodone-based painkiller Zohydro ER, even as a judge found that the pharmaceutical company’s planned generic version of the drug infringed the patents.

U.S. Circuit Judge William C. Bryson, sitting by designation in Delaware federal court, said in a 109-page opinion following a bench trial that although Alvogen’s proposed drug infringed Pernix Ireland Pain DAC and Pernix Therapeutics LLC’s patents, all of the asserted claims on the patents at issue were invalid for obviousness over a combination of previous patent applications known as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!